1Ojo AO, Hanson JA, Wolfe RA, et al. Long-term survival in renal transplant recipients with graft function. Kidney Int, 2000, 57 ( 1 ) : 307 -313. 被引量：1
2U.S. Renal Data System. USRDS 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, Bethesda, National Institute of Health, National Institute of Diabetes and Digestive and Kidney Disease, 2007. 被引量：1
3Simmons EM, Langone A, Sezer MT, et al. Effect of renal transplantation on biomarkers of inflammation and oxidative stress in end-stage renal disease patients. Transplantation, 2005,79( 8 ) : 914 - 919. 被引量：1
4Ducloux D, Kazory A, Chalopin JM. Predicting coronary heart disease in renal transplant recipients: a prospective study. Kidney Int, 2004,66(1) : 441 -447. 被引量：1
5Ojo AO. Cardiovascular complications after renal transplantation and their prevention. Transplantation. 2006,82 (5) :603 - 611. 被引量：1
6Kalil RS, Hudson SL, Gaston RS. Determinants of cardiovascular mortality after renal transplantation: a role for cytomegalovirus? Am J Transplant, 2003,3( 1 ) :79 -81. 被引量：1
7Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension, 2003, 42 (6): 1206 - 1252. 被引量：1
8Opelz G, Zeier M, Laux G, et al. No improvement of patient or graft survival in transplant recipients with angiotensin-converting enzyme inhibitors or angiotensin Ⅱ type 1 receptor blockers: A collaborative transplant study report. J Am Soc Nephrol, 2006 ( 11 ) , 17:3257 - 3262. 被引量：1
9Kasiske BL, Anjum S, Shah R, et al. Hypertension after kidney transplantation. Am J Kidney Dis, 2004, 43 (6) : 1071 - 1081. 被引量：1
10Kidney Disease Outcomes Quality Initiative (K/DOQI): K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis, 2004, 43 (5 Suppl 1 ) : S1 - S290. 被引量：1
2Womer KL, Vella JP, Sayegh MH. Chronic allograft dysfunction:mechanisms and new approaches to therapy. Seminars in Nephrology,2000,20(2): 126. 被引量：1
3Dimeny E, Fellstrom B, Larsson E,et al. Hyperlipoproteinemia in renal transplant recipients: is there a linkage with chronic vascular rejection? Transplant Proc, 1993,25 (2): 2065. 被引量：1
5Vathsala A, Weinberg RB,Schoenberg L, et al. Lipid abnormalities in cyclosporine-prednisone-treated renal transplant recipients. Transplantation, 1989,48 ( 1 ) :37. 被引量：1
6Starzl TE, Todo S, Fung J,et al. FK 506 for liver, kidney, and pancreas transplantation. Lancet, 1989,28,2 (8670): 1000. 被引量：1
7Hamar P, Mǘller V, Kohnle M,et al. Metabolic factors have a major impact on outcome of renal kidney transplantation. Transplantation,1997,64(8) :1135. 被引量：1
8Kasiske BL, Tortoriee KL, Heim-Duthoy KL,et al. The adverse impact of cyclosporin on serum lipids in renal transplant recipients. Am J Kidney Dis, 1991,17 ( 6 ) :700. 被引量：1
9Jindal RM, Popescu Ⅰ, Emre S. Serum lipid changes in liver transplant recipients in a prospective trial of cyclosporine versus FK 506.Transplantation, 1994,57 (9): 1395. 被引量：1
10Pirsch JD, Miller J, Deirhoi MH, et al. A comparison of tacrolimus ( FK506 ) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation1997,63 (7) :977. 被引量：1
